These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32388811)

  • 1. GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer.
    El-Arabey AA; Abdalla M; Abd-Allah AR
    Hum Cell; 2020 Jul; 33(3):904-906. PubMed ID: 32388811
    [No Abstract]   [Full Text] [Related]  

  • 2. GATA3 as a regulator for naughty cancer-associated fibroblasts in the microenvironment of high-grade serous ovarian cancer.
    El-Arabey AA; Abdalla M
    Hum Cell; 2021 Nov; 34(6):1934-1936. PubMed ID: 34432264
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer.
    El-Arabey AA; Abdalla M
    Hum Cell; 2022 Jul; 35(4):1298-1300. PubMed ID: 35459984
    [No Abstract]   [Full Text] [Related]  

  • 4. GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
    Chen HJ; Huang RL; Liew PL; Su PH; Chen LY; Weng YC; Chang CC; Wang YC; Chan MW; Lai HC
    Int J Cancer; 2018 Dec; 143(12):3106-3119. PubMed ID: 30006927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
    Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
    Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
    Voutsadakis IA
    Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.
    Vathipadiekal V; Saxena D; Mok SC; Hauschka PV; Ozbun L; Birrer MJ
    PLoS One; 2012; 7(1):e29079. PubMed ID: 22272227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma.
    Yang S; Zhang Y; Meng F; Liu Y; Xia B; Xiao M; Xu Y; Ning X; Li H; Lou G
    Biomarkers; 2013 May; 18(3):257-63. PubMed ID: 23566000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 13. Redefining the standard of care for low-grade serous ovarian cancer.
    Manning-Geist BL; Cantor T; O'Cearbhaill RE; Grisham RN
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):205-226. PubMed ID: 38805312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
    BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of two-tier grading system of ovarian serous carcinoma].
    Zhang J; Guo XQ; Liu JS
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):739-41. PubMed ID: 22321346
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-neoplastic Fallopian Tube Epithelium Carrying Gene Mutations of a Novel SOX2 Repressor Region is Soil of High-grade Serous Ovarian Cancer.
    Hirohashi Y; Torigoe T
    EBioMedicine; 2016 Aug; 10():17-8. PubMed ID: 27423191
    [No Abstract]   [Full Text] [Related]  

  • 18. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.
    Wu J; Lai M; Shao C; Wang J; Wei JJ
    Oncol Rep; 2015 Sep; 34(3):1494-502. PubMed ID: 26165228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX2 expression associates with stem cell state in human ovarian carcinoma.
    Bareiss PM; Paczulla A; Wang H; Schairer R; Wiehr S; Kohlhofer U; Rothfuss OC; Fischer A; Perner S; Staebler A; Wallwiener D; Fend F; Fehm T; Pichler B; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
    Cancer Res; 2013 Sep; 73(17):5544-55. PubMed ID: 23867475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
    Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
    Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.